Exenatide
Byetta (immediate-release) · Bydureon BCise (extended-release)
Exenatide Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 2 diabetes mellitus — glycemic control (Byetta IR) | Adults | Adjunctive to diet & exercise | FDA Approved |
| Type 2 diabetes mellitus — glycemic control (Bydureon BCise ER) | Adults and pediatric patients ≥10 years | Adjunctive to diet & exercise | FDA Approved |
Exenatide was the first GLP-1 receptor agonist approved for clinical use (April 2005, Byetta). The immediate-release formulation is given twice daily as an adjunct to diet and exercise in adults with type 2 diabetes, typically added to existing metformin and/or sulfonylurea therapy when glycemic targets are not met. The extended-release formulation (Bydureon BCise) provides once-weekly dosing and holds an additional pediatric indication for patients aged 10 years and older. Coadministration of different exenatide-containing products is not recommended. Exenatide is not a substitute for insulin and should not be used in type 1 diabetes or diabetic ketoacidosis.
In August 2024, the applicant for Byetta (IR) notified the FDA of its plan to permanently withdraw the product from sale. The original Bydureon vial/pen formulation was withdrawn from the market in March 2021. Bydureon BCise (ER autoinjector) remains the currently marketed exenatide formulation. Clinicians should verify current supply availability before initiating new patients on Byetta IR.
Obesity / weight management (without diabetes): Exenatide has been studied for weight reduction in non-diabetic obese individuals, with modest weight loss demonstrated in clinical trials. Evidence quality: Moderate.
Polycystic ovary syndrome (PCOS): Limited studies suggest exenatide may improve metabolic and hormonal parameters in overweight women with PCOS. Evidence quality: Low.
Non-alcoholic fatty liver disease (NAFLD): Small trials have shown improvements in hepatic steatosis and liver enzymes. Evidence quality: Low.
Exenatide Dosing
Immediate-Release (Byetta) — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — initial add-on to metformin, SFU, or both | 5 mcg SC BID | 10 mcg SC BID | 20 mcg/day | Increase to 10 mcg BID after 1 month Inject 0–60 min before morning & evening meals; ≥6 h apart |
| T2DM — add-on to thiazolidinedione ± metformin | 5 mcg SC BID | 10 mcg SC BID | 20 mcg/day | Same titration schedule Monitor for hypoglycemia if combined with SFU |
| T2DM — add-on to basal insulin ± oral agents | 5 mcg SC BID | 10 mcg SC BID | 20 mcg/day | Consider reducing insulin dose by 20% if HbA1c ≤8% to prevent hypoglycemia Inject in separate site from insulin; never mix |
| T2DM — monotherapy (when metformin intolerant) | 5 mcg SC BID | 10 mcg SC BID | 20 mcg/day | Lower hypoglycemia risk as monotherapy Not first-line; consider after oral agent failure |
Extended-Release (Bydureon BCise) — Adults & Pediatric ≥10 years
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — once-weekly regimen (adults & pediatric ≥10 y) | 2 mg SC weekly | 2 mg SC weekly | 2 mg/week | Fixed dose, no titration required Administer any time of day, with or without meals; same day each week |
| Transition from Byetta IR to Bydureon BCise ER | 2 mg SC weekly | 2 mg SC weekly | 2 mg/week | Start ER 1 day after last IR dose Transient glucose elevation may occur for ~2 weeks during transition |
Renal Dose Adjustments
| Renal Function (CrCl) | IR (Byetta) | ER (Bydureon BCise) | Notes |
|---|---|---|---|
| Mild impairment (50–80 mL/min) | No adjustment | No adjustment | PK exposure similar to normal function (FDA PI) |
| Moderate impairment (30–50 mL/min) | Use with caution | Use with caution | Exercise caution when initiating or escalating from 5 to 10 mcg |
| Severe impairment / ESRD (<30 mL/min) | Not recommended | Not recommended | GI adverse effects poorly tolerated in ESRD on dialysis |
The 1-month initiation period at 5 mcg BID is primarily for gastrointestinal tolerability, not efficacy. Nausea typically peaks in the first 2–4 weeks and subsides with continued use. Advising patients to eat smaller meals, avoid high-fat foods, and stop eating when satiated can meaningfully reduce nausea burden during titration.
Pharmacology of Exenatide
Mechanism of Action
Exenatide is a synthetic 39-amino-acid peptide that shares approximately 53% sequence homology with native human glucagon-like peptide-1 (GLP-1). It binds and activates the GLP-1 receptor, producing several glucose-lowering effects that are collectively glucose-dependent. In the presence of elevated blood glucose, exenatide enhances insulin secretion from pancreatic beta cells, restoring the characteristically absent first-phase insulin response seen in type 2 diabetes. Simultaneously, it suppresses inappropriately elevated postprandial glucagon release, which curbs hepatic glucose output. Exenatide also slows gastric emptying, attenuating the rate of postprandial glucose appearance in the circulation. Unlike native GLP-1, exenatide resists rapid degradation by dipeptidyl peptidase-IV (DPP-IV), enabling a clinically useful half-life of 2.4 hours after subcutaneous injection. These combined incretin-related actions provide fasting and postprandial glucose lowering with a low intrinsic risk of hypoglycemia when used without concomitant insulin secretagogues.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ~100% (SC); Tmax ~2.1 h; plasma levels detectable for ~10 h post-dose | Rapid onset; injection site (abdomen, thigh, upper arm) does not meaningfully affect exposure |
| Distribution | Vd = 28.3 L; 53% sequence homology to GLP-1 | Moderate distribution volume consistent with a peptide that remains largely extracellular |
| Metabolism | Proteolytic degradation in renal tubules; resistant to DPP-IV cleavage; no CYP involvement | No hepatic metabolism; hepatic impairment does not require dose adjustment; minimal drug-drug interaction via CYP pathways |
| Elimination | Primarily renal via glomerular filtration; t½ = 2.4 h (IR); CL = 9.1 L/h | Dose-independent clearance; exposure increases in severe renal impairment (CrCl <30) warranting avoidance |
Side Effects of Exenatide
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 44% (10 mcg BID) | Most common adverse reaction; dose-dependent; frequency and severity typically decrease over 2–4 weeks with continued therapy |
| Vomiting | 13% (10 mcg BID) | Usually co-occurs with nausea; may contribute to dehydration in susceptible patients |
| Diarrhea | 13% (10 mcg BID) | Monitor for volume depletion, especially in patients on diuretics or with renal impairment |
| Hypoglycemia (with SFU) | 36% (10 mcg + SFU) | Much lower risk as monotherapy or with metformin alone (~4–5%); consider SFU dose reduction |
| Injection-site reactions (ER formulation) | 10.5% (BCise) | Subcutaneous nodules at injection site; do not manipulate nodules (risk of increased drug absorption) |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Feeling jittery | 9% | More common at 10 mcg; typically transient and self-limiting |
| Dizziness | 6% | May relate to GI-mediated volume depletion; advise adequate hydration |
| Headache | 9% | Comparable to placebo in some trials; usually does not necessitate discontinuation |
| Dyspepsia | 6% | Part of the broader GI side-effect profile; consider smaller, more frequent meals |
| Constipation | 6% | Related to slowed gastric emptying; encourage adequate fluid and fibre intake |
| Asthenia | 4% | Generally mild; assess for concurrent hypoglycemia or dehydration |
| Decreased appetite | 1–2% | Contributes to weight loss effect; usually not clinically concerning unless nutrition inadequate |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Acute pancreatitis | 0.4% (ER trials) | Any time; highest risk in early months | Discontinue immediately; initiate supportive care; do not re-challenge; consider alternative antidiabetic therapy |
| Acute kidney injury | Rare (postmarketing) | Usually with GI-mediated dehydration | Monitor renal function; ensure adequate hydration; withhold during severe vomiting/diarrhea |
| Anaphylaxis / angioedema | Very rare (postmarketing) | Any time | Discontinue permanently; emergency treatment; do not re-expose to exenatide |
| Drug-induced immune-mediated thrombocytopenia | Very rare (postmarketing) | Variable | Discontinue immediately; do not re-expose to exenatide; may be fatal |
| Gallbladder disease (cholelithiasis / cholecystitis) | 1.9% (vs 1.4% placebo) | Any time during treatment | Gallbladder imaging and appropriate clinical follow-up if cholelithiasis suspected |
| Thyroid C-cell tumors (ER only) | Observed in rodents; unknown in humans | Uncertain | Contraindicated in patients with personal/family history of MTC or MEN 2; counsel on symptoms of thyroid tumors |
| Pulmonary aspiration (peri-operative) | Rare (postmarketing) | During general anesthesia / deep sedation | Inform surgical team; consider withholding pre-operatively per institutional guidance |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Nausea | 3–9% | Higher in combination vs monotherapy trials; dose-dependent |
| Vomiting | 1–5% | Most withdrawals occurred within the first 8 weeks |
| Other GI adverse effects | <1% | Includes diarrhea, dyspepsia, abdominal pain |
Nausea is the primary driver of early discontinuation and is dose-dependent, peaking during the first 4–8 weeks. The 1-month titration from 5 mcg to 10 mcg BID is designed to improve tolerability. Practical strategies include advising patients to eat slowly, reduce portion sizes, avoid fatty or overly sweet foods, and ensure adequate hydration. If nausea persists beyond 8 weeks at the same dose, consider whether the clinical benefit justifies continuation or whether switching to a weekly GLP-1 RA formulation (which typically causes less nausea) would be appropriate.
Exenatide Drug Interactions
Exenatide is not metabolized via cytochrome P450 enzymes and has no known CYP-mediated interactions. Its primary interaction pathway is through delayed gastric emptying, which can reduce the rate and extent of absorption of concomitantly administered oral medications. Oral drugs requiring rapid GI absorption or those with narrow therapeutic indices deserve particular attention.
Monitoring for Exenatide
-
HbA1c
Baseline, then every 3–6 months
Routine Primary efficacy marker; expected reduction of 0.5–1.0% from baseline. Assess response adequacy by 3–6 months; consider alternative therapy if insufficient response or worsening glycemic control (may indicate anti-drug antibody formation). -
Renal Function
Baseline, then periodically
Routine Serum creatinine and eGFR before initiation. Monitor more frequently during dose escalation and in patients reporting persistent nausea, vomiting, or diarrhea that could lead to dehydration and acute kidney injury. -
Blood Glucose
Ongoing self-monitoring
Routine Especially important when combined with sulfonylureas or insulin. Educate patients on recognizing and treating hypoglycemia symptoms. -
GI Tolerability
First 4–8 weeks
Trigger-based Assess nausea severity and hydration status. If persistent severe vomiting or diarrhea develops, evaluate for dehydration and renal impairment before continuing therapy. -
Pancreatitis Signs
Ongoing clinical vigilance
Trigger-based Instruct patients to report persistent severe abdominal pain radiating to the back with or without vomiting. Lipase/amylase are not recommended as routine screening but should be checked if clinical suspicion arises. -
Body Weight
Baseline, then every visit
Routine Weight loss of 2–3 kg over 6 months is commonly observed. Monitor for excessive or unintended weight loss, particularly in elderly or nutritionally vulnerable patients. -
Injection Sites
Each visit (ER formulation)
Trigger-based Inspect for subcutaneous nodules (common with ER microsphere formulation). Advise patients not to massage or manipulate nodules, as this can increase drug absorption and worsen systemic side effects. -
INR (if on warfarin)
Increased frequency at initiation
Trigger-based Postmarketing reports of elevated INR with bleeding. Monitor INR closely when starting, adjusting, or stopping exenatide in warfarin-treated patients until values are stable.
Contraindications & Cautions
Absolute Contraindications
- Prior severe hypersensitivity reaction to exenatide or any excipient — including anaphylaxis, angioedema, or severe skin reactions. Do not re-challenge.
- History of drug-induced immune-mediated thrombocytopenia from exenatide products — re-exposure may cause recurrent life-threatening thrombocytopenia with fatal bleeding.
- Personal or family history of medullary thyroid carcinoma (MTC) — applies to the extended-release formulation (Bydureon BCise). Thyroid C-cell tumors observed in rodent studies at clinically relevant doses.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — applies to the extended-release formulation. Elevated baseline risk of MTC makes any additional thyroid C-cell stimulation unacceptable.
Relative Contraindications (Specialist Input Recommended)
- History of pancreatitis — exenatide has not been studied in this population; alternative antidiabetic therapy should be considered. If used, requires documented risk-benefit discussion and close surveillance for recurrence.
- Moderate renal impairment (CrCl 30–50 mL/min) — use with caution during initiation and dose escalation; GI-mediated dehydration can precipitate acute kidney injury.
- History of anaphylaxis or angioedema with another GLP-1 receptor agonist — cross-reactivity is unknown; closely monitor and inform patient of risk.
Use with Caution
- Severe gastroparesis or severe gastrointestinal disease — exenatide slows gastric emptying and commonly causes nausea and vomiting, which could exacerbate pre-existing GI motility disorders.
- Patients on concomitant insulin secretagogues or insulin — increased hypoglycemia risk; consider dose reduction of the secretagogue or insulin.
- Patients scheduled for elective surgery — gastric emptying delay poses aspiration risk under general anesthesia or deep sedation; inform the surgical team.
- Renal transplant recipients — limited data and potential for renal complications; use with caution.
- Elderly patients — no specific dose adjustment required, but dehydration risk may be higher; ensure adequate fluid intake.
Exenatide extended-release causes dose-dependent and duration-dependent increases in thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures in rats. It remains unknown whether exenatide ER causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. Bydureon BCise is contraindicated in patients with a personal or family history of MTC and in patients with MEN 2. Counsel all patients on the potential risk and advise them to report symptoms such as a neck mass, dysphagia, dyspnea, or persistent hoarseness.
Patient Counselling
Purpose of Therapy
Exenatide is an injectable medication that works alongside your body’s own insulin system to lower blood sugar after meals and between meals. It is used together with diet, exercise, and sometimes other diabetes medicines to help manage type 2 diabetes. It is not insulin and does not replace insulin. Exenatide often leads to modest weight loss, which can be an additional benefit for many patients with type 2 diabetes.
How to Take
For the twice-daily pen (Byetta), inject in the thigh, abdomen, or upper arm within the 60-minute window before your morning and evening meals. Meals should be at least 6 hours apart. Do not inject after eating. Rotate injection sites with each dose. Store unopened pens in the refrigerator; after first use, the pen can be kept at room temperature (below 25°C / 77°F) for up to 30 days. For the once-weekly autoinjector (Bydureon BCise), inject on the same day each week at any time of day, with or without food.
Sources
- BYETTA (exenatide) injection, for subcutaneous use. Full Prescribing Information. AstraZeneca Pharmaceuticals LP. Revised May 2025. FDA Label Primary source for Byetta IR dosing, adverse reactions, pharmacokinetics, contraindications, and drug interactions.
- BYDUREON BCise (exenatide) extended-release for injectable suspension. Full Prescribing Information. AstraZeneca Pharmaceuticals LP. Revised November 2024. FDA Label Primary source for extended-release dosing, boxed warning on thyroid C-cell tumors, and pediatric indication.
- BYDUREON (exenatide extended-release) for injectable suspension. Full Prescribing Information. Revised 2018. FDA Label Historical reference for the original weekly formulation; marketing discontinued March 2021.
- Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi:10.1056/NEJMoa1612917 EXSCEL trial (n=14,752): demonstrated cardiovascular safety (noninferiority) of once-weekly exenatide ER; all-cause mortality 14% lower (HR 0.86, not powered for superiority).
- DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100. doi:10.2337/diacare.28.5.1092 Pivotal 30-week RCT showing significant HbA1c and weight reduction with exenatide added to metformin; key source of adverse reaction incidence data.
- Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635. doi:10.2337/diacare.27.11.2628 Pivotal 30-week RCT demonstrating efficacy with sulfonylurea; documented higher hypoglycemia rates with the SFU combination.
- Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091. doi:10.2337/diacare.28.5.1083 Third pivotal 30-week trial; triple-therapy arm (MET + SFU + exenatide); largest of the three pivotal studies.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1). doi:10.2337/dc25-SINT Current ADA guidelines positioning GLP-1 RAs as preferred second-line agents in T2DM, particularly with established cardiovascular disease or obesity.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034 ADA/EASD consensus framework placing GLP-1 RAs in the treatment algorithm based on cardiorenal and weight considerations.
- Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082–3089. doi:10.1210/jc.2002-021545 Early pharmacodynamic study demonstrating restoration of first-phase insulin secretion and glucose-dependent insulin action with exenatide.
- Cirincione B, Edwards J, Engel SS, et al. Population pharmacokinetics of exenatide. Br J Clin Pharmacol. 2017;83(3):517–526. doi:10.1111/bcp.13135 Population PK model characterizing exenatide IR absorption, distribution, and clearance; source for Vd (28.3 L), CL (9.1 L/h), and t½ (2.4 h) data.
- Fineman MS, Mace KF, Engel SS, et al. Clinical relevance of anti-exenatide antibodies. Diabetes Obes Metab. 2012;14(6):546–554. doi:10.1111/j.1463-1326.2012.01561.x Analysis of immunogenicity across exenatide clinical trials; found that high-titer antibodies attenuated glycemic response in approximately 3% of patients.
- Bethel MA, Mentz RJ, Merrill P, et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. Diabetes Care. 2020;43(2):446–452. doi:10.2337/dc19-1065 EXSCEL subgroup analysis examining exenatide safety and efficacy across baseline renal function categories.